BBLGW
Bone Biologics Corporation
Price Chart
Latest Quote
$13.00
+0.00 (+0.00%)
Current Price
| Previous Close | $13.00 |
| Open | $9.97 |
| Day High | $13.00 |
| Day Low | $13.00 |
| Volume | 1 |
Stock Information
| Cash Equivalents | $4.53M |
| Net Income | $-2.86M |
| EPS (TTM) | $-0.14 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-2.86M |
| Book/sh | $2.60 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 14.67 |
| Current Ratio | 16.09 |
Returns & Margins
| ROA | -46.08% |
| ROE | -75.40% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 5.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $14.40 |
| SMA50 | $15.85 |
| SMA200 | $18.08 |
| RSI | nan |
| Shares Float | 1.79M |
| Volatility | 0.53 |
Performance History
| Week | +0.00% |
| Month | +20.83% |
| Quarter | -27.50% |
| 6 Months | -1.36% |
| YTD | -6.45% |
| Year | -3.33% |
| 3 Years | +728.57% |
| 10 Years | +1118.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $14.50 | 0 |
| 2026-07-16 | $14.50 | 0 |
| 2026-07-15 | $14.50 | 0 |
| 2026-07-14 | $14.50 | 0 |
| 2026-07-13 | $14.50 | 0 |
| 2026-07-10 | $14.50 | 0 |
| 2026-07-09 | $14.50 | 0 |
| 2026-07-08 | $14.50 | 0 |
| 2026-07-07 | $14.50 | 0 |
| 2026-07-06 | $14.50 | 0 |
| 2026-07-02 | $14.50 | 0 |
| 2026-07-01 | $14.50 | 0 |
| 2026-06-30 | $14.50 | 0 |
| 2026-06-29 | $14.50 | 0 |
| 2026-06-26 | $14.50 | 0 |
| 2026-06-25 | $14.50 | 0 |
| 2026-06-24 | $14.50 | 0 |
| 2026-06-23 | $14.50 | 0 |
| 2026-06-22 | $14.50 | 900 |
| 2026-06-18 | $12.45 | 600 |
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | $0 |
| Cost Of Revenue | - | - | - | $0 |
| Expenses | ||||
| Total Expenses | $3,234,942 | $4,219,161 | $9,428,303 | $3,665,173 |
| Other Income Expense | $3,967 | $51,081 | $477,704 | $2,912,267 |
| Net Non Operating Interest Income Expense | $121,984 | $55,660 | $1,868 | $-731,714 |
| Operating Expense | $3,234,942 | $4,219,161 | $9,428,303 | $3,665,173 |
| General And Administrative Expense | $2,174,751 | $2,088,776 | $2,520,479 | $2,085,875 |
| Interest Expense | - | - | - | $0 |
| Total Other Finance Cost | - | - | - | $731,714 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Net Interest Income | $121,984 | $55,660 | $1,868 | $-731,714 |
| Interest Income | $121,984 | $55,660 | $1,868 | $0 |
| Normalized Income | $-3,112,958 | $-4,163,501 | $-9,426,435 | $-4,396,887 |
| Net Income From Continuing And Discontinued Operation | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Total Operating Income As Reported | $-3,234,942 | $-4,219,161 | $-9,428,303 | $-3,665,173 |
| Net Income Common Stockholders | $-3,108,991 | $-7,324,924 | $-8,948,731 | $-1,484,620 |
| Net Income | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Net Income Including Noncontrolling Interests | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Net Income Continuous Operations | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Pretax Income | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Interest Income Non Operating | $121,984 | $55,660 | $1,868 | $0 |
| Operating Income | $-3,234,942 | $-4,219,161 | $-9,428,303 | $-3,665,173 |
| Special Income Charges | - | $0 | $-414,989 | $0 |
| Gross Profit | - | - | - | $0 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,238,909 | $-4,270,242 | $-9,906,007 | $-6,577,440 |
| Total Unusual Items | $3,967 | $51,081 | $477,704 | $2,912,267 |
| Total Unusual Items Excluding Goodwill | $3,967 | $51,081 | $477,704 | $2,912,267 |
| EBITDA (Bullshit earnings) | $-3,234,942 | $-4,219,161 | $-9,428,303 | $-3,665,173 |
| EBIT | $-3,234,942 | $-4,219,161 | $-9,428,303 | $-3,665,173 |
| Diluted NI Availto Com Stockholders | $-3,108,991 | $-7,324,924 | $-8,948,731 | $-1,484,620 |
| Otherunder Preferred Stock Dividend | $0 | $3,212,504 | $0 | - |
| Gain On Sale Of Security | $3,967 | $51,081 | $892,693 | $2,912,267 |
| Research And Development | $1,060,191 | $2,130,385 | $6,907,824 | $1,579,298 |
| Selling General And Administration | $2,174,751 | $2,088,776 | $2,520,479 | $2,085,875 |
| Other Gand A | $2,174,751 | $2,088,776 | $2,520,479 | $2,085,875 |
| Other Special Charges | - | - | $414,989 | - |
| Tax Provision | - | - | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Total Assets | $5,796,135 | $3,861,369 | $3,737,763 | $8,495,237 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $5,796,135 | $3,861,369 | $3,737,763 | $8,495,237 |
| Prepaid Assets | $451,918 | $536,238 | $711,194 | $956,925 |
| Receivables | $9,895 | $0 | $328,844 | $579,910 |
| Accrued Interest Receivable | $9,895 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $5,334,322 | $3,325,131 | $3,026,569 | $7,538,312 |
| Cash And Cash Equivalents | $5,334,322 | $3,325,131 | $3,026,569 | $7,538,312 |
| Cash Financial | $5,334,322 | $3,325,131 | $3,026,569 | $7,538,312 |
| Other Receivables | - | - | $328,844 | $579,910 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $418,587 | $377,712 | $831,402 | $2,547,929 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $418,587 | $377,712 | $831,402 | $2,547,929 |
| Other Current Liabilities | $703 | $4,670 | $55,751 | $1,659,468 |
| Payables And Accrued Expenses | $417,884 | $373,042 | $775,651 | $104,786 |
| Payables | $417,884 | $373,042 | $360,662 | $104,786 |
| Accounts Payable | $417,884 | $373,042 | $360,662 | $104,786 |
| Current Deferred Liabilities | - | $0 | $0 | $783,675 |
| Current Notes Payable | - | - | - | - |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Total Equity Gross Minority Interest | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Stockholders Equity | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Retained Earnings | $-88,130,369 | $-85,021,378 | $-80,908,958 | $-71,960,227 |
| Other | ||||
| Ordinary Shares Number | $1,795,260 | $492,330 | $89,039 | $10,626 |
| Share Issued | $1,795,260 | $492,330 | $89,039 | $10,626 |
| Tangible Book Value | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Invested Capital | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Working Capital | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Total Capitalization | $5,377,548 | $3,483,657 | $2,906,361 | $5,947,308 |
| Additional Paid In Capital | $93,506,122 | $88,504,543 | $83,814,785 | $77,907,471 |
| Capital Stock | $1,795 | $492 | $534 | $64 |
| Common Stock | $1,795 | $492 | $534 | $64 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Deferred Revenue | - | $0 | $0 | $783,675 |
| Current Accrued Expenses | - | $0 | $414,989 | - |
| Treasury Shares Number | - | - | $0 | - |
| Line Of Credit | - | - | - | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,691,150 | $-4,124,935 | $-9,555,904 | $-3,566,913 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,691,150 | $-4,124,935 | $-9,555,904 | $-3,566,913 |
| Cash Flow From Continuing Operating Activities | $-2,691,150 | $-4,124,935 | $-9,555,904 | $-3,566,913 |
| Operating Gains Losses | $-3,967 | $-51,081 | $-892,693 | $-2,912,267 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,700,341 | $2,616,315 | $5,044,161 | $4,429,860 |
| Financing Cash Flow | $4,700,341 | $4,423,497 | $5,044,161 | $4,429,860 |
| Cash Flow From Continuing Financing Activities | $4,700,341 | $4,423,497 | $5,044,161 | $4,429,860 |
| Net Common Stock Issuance | $4,700,341 | $2,616,315 | $5,044,161 | $4,429,860 |
| Common Stock Issuance | $4,700,341 | $2,616,315 | $5,044,161 | $4,429,860 |
| Other | ||||
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $5,334,322 | $3,325,131 | $3,026,569 | $7,538,312 |
| Beginning Cash Position | $3,325,131 | $3,026,569 | $7,538,312 | $6,675,365 |
| Changes In Cash | $2,009,191 | $298,562 | $-4,511,743 | $862,947 |
| Proceeds From Stock Option Exercised | $0 | $1,807,182 | $0 | - |
| Change In Working Capital | $165,450 | $-150,253 | $132,921 | $-168,373 |
| Change In Payables And Accrued Expense | $91,025 | $-325,209 | $670,865 | $4,877 |
| Change In Accrued Expense | $0 | $-414,989 | $414,989 | $0 |
| Change In Payable | $91,025 | $89,780 | $255,876 | $4,877 |
| Change In Account Payable | $91,025 | $89,780 | $255,876 | $4,877 |
| Change In Prepaid Assets | $84,320 | $174,956 | $245,731 | $-956,925 |
| Change In Receivables | $-9,895 | - | - | - |
| Stock Based Compensation | $256,358 | $188,819 | $152,599 | $266,633 |
| Gain Loss On Investment Securities | $-3,967 | $-51,081 | $-892,693 | $-2,912,267 |
| Net Income From Continuing Operations | $-3,108,991 | $-4,112,420 | $-8,948,731 | $-1,484,620 |
| Interest Paid Supplemental Data | - | $0 | $0 | $0 |
| Change In Other Working Capital | - | - | $-783,675 | $783,675 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Other Non Cash Items | - | - | - | $731,714 |
Fetched: 2026-07-15